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Gemcitabine in Brief versus Prolonged Low-Dose Infusion,
both Combined with Cisplatin, for Advanced Non-small
Cell Lung Cancer
A Randomized Phase II Clinical Trial
Matjaz Zwitter, MD, PhD,*† Viljem Kovac, MD, MSc,* Uros Smrdel, MD, MSc,*
Martina Vrankar, MD,* and Vesna Zadnik, MD, PhD*
Objective: Gemcitabine in low dose in prolonged infusion is a
treatment with documented activity against a variety of tumors. We
here report the first randomized trial to compare standard brief and
low-dose prolonged infusion of gemcitabine.
Patients and Methods: Eligible patients had non-small cell lung
cancer in stage IIIB (wet) or IV, Karnofsky performance status 100
to 70 (Eastern Cooperative Oncology Group 0–2), measurable
disease, were chemonaïve and fulfilled the standard criteria for
chemotherapy. In arm A (standard treatment), gemcitabine was
given at 1250 mg/m2 in 20 to 30 minutes and in arm B (prolonged
infusion) at 250 mg/m2 in 6 hours infusion. All patients received
gemcitabine on days 1 and 8 and cisplatin at 75 mg/m2 on day 2 of
a 3-week cycle for four cycles, followed by two cycles of gemcit-
abine as monotherapy.
Results: A total of 249 patients (188 men and 61 women, median
age 58 years) were randomized between arm A (125 patients) and
arm B (124 patients). Adenocarcinoma (53.9%) was the predomi-
nant histologic type; 92% of patients were in stage IV. The two
groups were balanced for prognostic factors; however, group A had
fewer patients with significant weight loss and no patient with lung
cancer as a second malignancy or after radiotherapy for brain
metastases. Grade 3 or greater toxicity was rare: anemia in 0.8 and
3.2%, neutropenia in 21.6 and 22.6%, thrombocytopenia in 0 and
1.6%, and nausea/vomiting in 4 and 8.1% for arms A and B,
respectively. Alopecia was seen in 54.5% of patients in arm B, as
compared with 9.7% in arm A. No patient died of treatment-related
toxicity. During cycle 5, 47.7% of patients in arm A and 60.7% in
arm B reported improved well-being, as compared with the status
before chemotherapy. Patients in arm A had no complete remission,
32.8% partial responses, 48% minimal responses or stable disease,
13.6% progressions, and 5.6% were not evaluable. For arm B, the
corresponding figures are as follows: complete remission 0.8%,
partial responses 46% (for overall response rate of 46.8%), minimal
responses or stable disease 36.3%, progression 12.1%, and not
evaluable 4.8%. Median progression-free survival was 5.5 and 6.0
months, median overall survival was 10.1 and 10.0 months, and
1-year survival was 46.6 and 41.1% for arms A and B, respectively.
For the 71 patients with squamous carcinoma, arm B seems superior
to arm A, as seen by the higher overall response rate (51.3 versus
35.5%), longer median progression-free survival (6.2 versus 4.9
months), and longer median survival (11.3 versus 8.5 months).
However, because of the small number of patients, these differences
did not reach the level of statistical significance.
Conclusion: In the treatment of advanced non-small cell lung
cancer, gemcitabine in low dose in prolonged infusion in combina-
tion with cisplatin has low toxicity and has activity comparable with
gemcitabine in higher dose in standard brief infusion. Low-dose
gemcitabine may be preferred for incurable cancer among econom-
ically deprivileged patients. In addition, apparent superior activity
against squamous carcinoma opens new perspectives and deserves
further research.
Key Words: Non-small cell lung cancer, Gemcitabine, Prolonged
infusion, Cisplatin, Randomized clinical trial.
(J Thorac Oncol. 2009;4: 1148–1155)
Gemcitabine (usually in combination with a platinumcompound) is among the standard drugs for the treat-
ment of a variety of tumors, including non-small cell lung
cancer (NSCLC). For the usual 20- to 30-minute infusion
(dose rate 40–60 mg/m2/min) and for the moderately pro-
longed infusion at dose rate 10 mg/m2/min, the maximum-
tolerated dose (MTD) is 1500 mg/m2 or even higher.1,2 When
applied either in brief infusion or in moderately prolonged
infusion at 10 mg/m2/min, the activity and the toxicity profile
of gemcitabine are not superior to standard brief infusion.
Therefore, several recent trials concluded that no further
research of moderately prolonged gemcitabine is warranted.3–5
By contrast, MTD falls significantly with lower dose rates of
infusion of gemcitabine. With infusions lasting for 3, 6, or 24
hours, MTD falls to 450, 250, and 180 mg/m2, respectively.6–9
The explanation for this phenomenon lies in the saturation of
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deoxycytidine kinase, which occurs during 30-minute infu-
sion.10,11 This enzyme is needed for conversion of gemcitab-
ine into its active form gemcitabine-triphosphate. Although
short infusion of a relatively high dose leaves most of the
drug unmetabolized, prolonged infusion leads to higher in-
tracellular concentration of the active metabolite.12 Conse-
quently, a lower dose is needed for a comparable activity.
Several phase I and phase II clinical trials have shown
significant antitumor activity of gemcitabine in low dose in
long infusion. The spectrum of diseases includes cancers of
the lung, breast, pancreas, gallbladder, bladder, sarcomas,
refractory leukemias, and refractory Hodgkin’s disease.8,13–20
Although promising experience has been reported, most trials
were small and included heavily pretreated patients. Thus,
both the activity and toxicity of gemcitabine in low dose in
long infusion remain unclear.
As for the lung cancer, our group reported favorable
experience with gemcitabine in long infusion in combination
with cisplatin for advanced NSCLC.21 In a phase I to II trial,
chemonaive patients with advanced NSCLC received gem-
citabine in escalating doses from 130 mg/m2 to 170, 210, and
250 mg/m2 in 6 hours, combined with cisplatin at 75 mg/m2.
The mild toxicity, objective response rate of 46%, and me-
dian survival of 9.5 months allowed us to conclude that this
treatment has activity at least comparable with the standard
brief infusion of a much higher dose of the drug.
Recently, two other phase II trials also presented a
similar favorable experience with prolonged infusion of gem-
citabine and cisplatin for advanced NSCLC. A group from
Nanchang, China applied gemcitabine at 250 mg/m2/6 hr on
days 1 and 8 and cisplatin at 75 mg/m2 on day 2. Low toxicity
and a 39.3% response rate were reported.22 A group from
Mumbai applied gemcitabine at 350 mg/m2 (days 1 and 8)
and carboplatin at area under the curve 5 also given on day 1.
They concluded that treatment with low-dose prolonged
infusion of gemcitabine and standard carboplatin is effective
in advanced-stage NSCLC, has low toxicity, is safe even in
elderly patients, and can result in substantial saving in che-
motherapy cost.23
We here present experience from a phase II randomized
clinical trial, comparing standard brief infusion of gemcitab-
ine with the low-dose prolonged infusion, both in combina-
tion with cisplatin for patients with advanced NSCLC. Pri-
mary objectives of the trial were progression-free survival
and overall survival; secondary objectives were toxicity,
response rate, and quality of life.
PATIENTS AND METHODS
Eligibility Criteria
Eligible patients had microscopically confirmed
NSCLC; had stage IIIB with pleural effusion or stage IV;
Eastern Cooperative Oncology Group (ECOG) performance
status 0 to 2; were chemonaive; had no urgent local problems
such as superior vena cava syndrome, symptomatic brain
metastases, or severe bone pain; had measurable disease at a
nonirradiated site; had hemoglobin above 100 g/liter and
neutrophils, thrombocytes, creatinine clearance, and bilirubin
within normal limits; had no significant cardiovascular or
neurologic comorbidity or active infection; and gave written
consent to be enrolled in clinical trial. Previous surgery
and/or radiotherapy for another cancer were allowed for
patients in remission lasting more than 3 years.
If the patient was treated previously by radiotherapy, all
acute radiation-related toxicity should have been resolved;
the minimal interval to the beginning of chemotherapy was 3
weeks for total dose more than or equal to 30 Gy or 10 days
for total dose less than 30 Gy. Patients after surgery and
radiotherapy for brain metastases were eligible if they met
other eligibility criteria and were free of major neurologic
symptoms.
Initial Diagnostics
All patients had their standard diagnostics for lung
cancer, including blood tests, imaging with chest radiograph,
chest and upper abdominal computed tomography, abdominal
ultrasound, bone scan, bronchoscopy, and appropriate tissue
diagnostics. Precise measurement of the initial maximal tu-
mor diameter within 3 weeks before treatment was manda-
tory. In the absence of neurologic symptoms, the brain was
not screened for metastatic disease. Positron emission tomog-
raphy-computed tomography was not available.
ECOG scale was used to assess the initial performance
status. Weight loss during the last 3 months and smoking
status were recorded.
Registration and Randomization
Patients were registered for the trial with e-mail to data
manager of the unit of clinical research. Randomization
between arms A (standard chemotherapy) and B (low-dose
gemcitabine in long infusion), 1:1, was done using a com-
puter-generated sequence of random numbers. After registra-
tion, all patients were considered as participating in the trial,
regardless of the treatment which they actually received.
Treatment
Arm A—Standard Treatment
Gemcitabine 1250 mg/m2 in 20 to 30 minutes infusion
on days 1 and 8; Cisplatin 75 mg/m2 with appropriate hydra-
tion and antiemetics on day 2; Cycle was repeated on day 22.
Arm B—Prolonged Infusion
Gemcitabine 250 mg/m2 in 6 hours on days 1 and 8;
Cisplatin and cycle duration as above. After four cycles,
patients not in progression continued with two additional
cycles of gemcitabine as monotherapy, delivered either as
brief infusion (arm A) or prolonged infusion (arm B).
Treatment Modification and Supportive
Treatment
In case of grade 1 (National Cancer Institute-common
toxicity criteria, version 2.0) neutropenia and/or thrombocy-
topenia, the dose of gemcitabine was reduced to 75%; the
drug was omitted with grade 2 or greater neutro/thrombocy-
topenia. Cisplatin was reduced to 80% in case of grade 1
nephrotoxicity and was omitted in case of a higher level of
nephrotoxicity and/or grade 3 nausea or vomiting.
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All treatment was delivered in day hospital. Standard
hydration and antiemetics were given. Because our previous
phase I–II trial indicated a possible increased risk for throm-
boembolic events after low-dose gemcitabine in long infu-
sion, all patients in both treatment arms received low
molecular weight heparin for the duration of the active
treatment.
Evaluation for Response, Quality of Life, and
Toxicity
During cycles 3 and 5, imaging was repeated to assess
tumor response according to RECIST, using the same method
as during initial imaging.
ECOG performance status was recorded monthly. Dur-
ing cycles 3 and 5, quality of life was evaluated by the
European Organization for Research and Treatment of Can-
cer Lung Cancer Symptom Scale—observer and patient
scale. In addition, we used our own simplified scale for
assessment of quality of life: How do you feel in comparison
with your feeling prior to treatment?
1. much worse;
2. worse;
3. about the same;
4. better;
5. much better.
Side effects of treatment were assessed according to the
National Cancer Institute-common toxicity criteria, version 2.0.
Follow-Up, Evaluation for Progression, and
Second-Line Treatment
After treatment, patients were invited to follow-up
visits every second month during the first year and at longer
intervals thereafter. In addition to clinical examination and
blood tests, chest radiograph or other appropriate imaging
was repeated to assess the site(s) of active disease.
In case of progression, every effort was made toward
effective palliation of the leading symptoms. Additional sys-
temic treatment was always discussed with the patient and at
the tumor board. Treatment was never prolonged at the
expense of an unbearable quality of life.
Ethical Issues and Statistical Considerations
The investigators strictly followed recommendations of
the Declaration of Helsinki (1964, with later amendments)
and of the European Council Convention on Protection of
Human Rights in Bio-Medicine (Oviedo 1997). The protocol
was approved by the Institutional Review Board (Institute of
Oncology, Ljubljana) and by the National Committee for
Medical Ethics, Ministry of Health, Republic of Slovenia.
The data were described as the absolute numbers with
corresponding relative frequencies. A 2 test was used to
examine the difference in the prognostic factors between
arms. Progression-free survival has been defined as the time
from the date of randomization to the date of disease pro-
gression or death (two events, whichever occurred first).
Median progression-free and overall survivals were estimated
by Kaplan-Meier survival curves; groups were compared by
the log-rank test. The effects of the treatment modality on the
survival were analyzed by the Cox model, allowing us to
control the results for age, gender, histologic type, and weight
loss. A p value less than 0.05 was considered statistically
significant. Statistical analysis was performed using the SPSS
software package (version 16.0).
Because of the limited number of patients in a single-
institution trial, we could not aim at a statistically significant
difference in any of the observed parameters. Rather, the trial
size of 250 patients was defined according to the expected
accrual of patients in our institution within 3 years. Although
the limited size and low power of such a randomized phase II
trial rarely leads to a statistically clear comparison, it may
offer a valuable orientation for further clinical research.24
RESULTS
Recruitment of Patients
Between December 2003 and October 2006, all eligible
patients seen at the Institute of Oncology, Ljubljana, were
invited to participate, and more than 90% consented to join
the trial. In total, 250 patients were recruited in the trial. One
patient (initially randomized to arm B and currently still
alive) was later found to have metastatic breast cancer with
endobronchial extension of a metastasis, rather than primary
NSCLC, and was therefore excluded from all further analy-
ses. This leaves us with 125 patients in arm A and 124
patients in arm B.
As expected, men (188 or 75.5%) predominated women
(61 or 24.5%). Median age was 58 years, with a range of 40
to 79 years. Most patients were smokers; however, 31 pa-
tients (12.4%) were never smokers and an additional 65
patients (26.1%) have given up smoking more than 3 years
before current disease. Six patients, all of them randomized to
treatment B had previous other cancer: three were after
treatment for head and neck cancer, two had cervical cancer,
and two others had non-Hodgkin’s lymphoma of the stomach
and pheochromocytoma.
The distribution of patients between arms A and B
according to demographics and to prognostic factors is shown
in Table 1. There was no statistical significant difference
between arms in prognostic factors shown in Table 1 except
for significant difference in previous cancers (2 p  0.013)
and percentage of weight loss (2 p  0.015).
Adenocarcinoma (137 patients or 55.0%) was the most
common histologic type, followed by squamous carcinoma
(28.5%), NSCLC of poorly differentiated or unspecified type
(10.8%), and large-cell carcinoma (5.2%).
Only six patients had previous thoracic surgery. Thus,
most patients (243 or 97.6%) had active disease at the
primary site and/or regional lymph nodes. Only 20 patients
(8.0%) had stage IIIB disease confined to primary tumor,
pleura, and/or pericardium. Among 92.0% of patients with
metastatic disease, distant lung metastases (52.2%) were the
most common site, followed by bone (26.1%), suprarenals
(18.9%), distant lymph nodes and soft tissues (16.1%), and
liver (15.7%). Three patients (1.2%) had previous surgery
and radiotherapy for brain metastases.
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Distribution of patients among the two treatment
groups according to histology, stage, active sites of disease,
and initial hemoglobin and C-reactive protein levels is given
in Table 2.
Treatment
After registration and randomization into arm A and
before any treatment, a man aged 53 years developed symp-
toms of brain metastases. This patient was treated with
radiotherapy to the brain and later continued treatment with
gemcitabine as monotherapy. All other patients received at
least one cycle of chemotherapy according to the protocol.
Five or all six cycles of chemotherapy were given to 97
(77.6%) patients in arm A and to 97 (78.2%) patients in arm B.
The reasons for early termination of the treatment were tumor
progression (11.2 and 8.9% for arms A and B, respectively) and
toxicity, deterioration of patient’s performance status, or pa-
tient’s refusal (8.8 and 10.5% for arms A and B, respectively).
Toxicity
In general, both treatments were tolerated well. Grade 3
or greater hematologic toxicity was rare: anemia in 0.8 and
3.2%, neutropenia in 21.6 and 22.6%, and thrombocytopenia
in 0 and 1.6% for arms A and B, respectively. No patient had
febrile neutropenia. Thrombocytosis was common and
reached levels above 800  109/liter in 32 (12.8%) patients
(Table 3).
Of the nonhematologic toxicity, grade 2 nausea and/or
vomiting were common (19.2% in arm A and 22.6% in arm B).
Grade 3 nausea and/or vomiting were seen in 4.0 and 8.1%
TABLE 1. Demographics, Medical History, and General
Prognostic Factors
Arm A Standard
Gemicitabine–
Cisplatin
(n  125)
Arm B Low-Dose
Gemicitabine–
Cisplatin
(n  124)
Age, median (range) 58 (41–77) 59 (40–79)
Gender
Male 95 93
Female 30 31
Smoking
Never smoker 16 15
Former, quit at 3 yr 30 35
Former, quit at 3 yr 8 4
Smoked until current disease 48 44
Current smoker 23 26
Previous other cancer 0 6a
EGOG PS
0 49 46
1 46 51
2 30 27
Weight loss
5% 97 78
5% 28 46b
a p  0.013.
b p  0.015.
ECOG, Eastern Cooperative Oncology Group; PS, performance status.
TABLE 2. Histology, Stage, Tumor Sites, and Additional
Prognostic Factors
Arm A Standard
Gemicitabine–
Cisplatin
(n  125)
Arm B Low-Dose
Gemicitabine–
Cisplatin
(n  124)
Histology
Squamous 32 39
Adeno 65 72
Large cell 6 7
Poorly differentiated and NSCLC,
undefined
22 5
Stage
IIIB 9 11
IV 116 113
Sites of active disease
1 1 2
2 77 71
3 35 39
4 9 12
5 3 0
Lung primary  regional nodes 124 119
Pleura, pericardium 32 21
Lung—distant metastases 63 67
Liver 18 21
Suprarenals 26 21
Bone 31 34
Distant lymph nodes, soft tissues 17 23
Brain, after RT  surgery 0 3
Initial Hb (g/liter)
141 37 46
121–140 62 52
120 26 26
Initial CRP
10 43 39
11–50 48 52
51 32 33
Not done 2 0
NSCLC, non-small cell lung cancer; RT, radiation therapy; Hb, hemoglobin; CRP,
c-reactive protein.
TABLE 3. Hematological Toxicity
Grade
Arm A Standard
Gemicitabine–
Cisplatin
(n  125)
Arm B Low-Dose
Gemicitabine–
Cisplatin
(n  124)
Anemia 2 53 44
3 1 3
4 0 1
Neutropenia 2 30 31
3 21 26
4 6 2
Thrombocytopenia 2 0 3
3 0 2
Thrombocytosis 501–800 69 64
801–1000 13 10
1001 5 4
Median 592 544
Maximum 1386 1196
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for arms A and B, respectively. Grade 3 nephrotoxicity was
not seen, and a single patient in arm B had transient grade 4
nephrotoxicity.
Grade 2 alopecia was rare in the standard arm (9.7%)
and significantly more common in patients treated with long
infusion of gemcitabine (54.5%, p  0.01).
Response to Treatment and Assessment of
Quality of Life
Patients in arm A had no complete remission: 32.8%
partial responses; 48% minimal responses or stable disease;
13.6% progressions; and 5.6% not evaluable.
A single patient in arm B had pathologically docu-
mented complete response, as proven by resection of a
solitary bone metastasis and of the primary lung tumor. This
patient remained in remission for 49 months when brain
metastases were diagnosed. Partial responses were seen in
46%, and overall response rate was 46.8%. Minimal response
or stable disease was seen in 36.3%, progression in 12.1%,
whereas 4.8% were not evaluable.
Table 4 presents data on response to treatment and
assessment of performance status and patient’s self-assess-
ment of quality of life during the fifth cycle of chemotherapy.
There is a trend toward better responses, higher performance
status, and higher quality of life in arm B; still, the differences
do not reach the level of statistical significance.
Data from European Organization for Research and
Treatment of Cancer Lung Cancer Symptom Scale question-
naire were incomplete and were not further analyzed.
Progression-Free Survival, Second-Line
Treatment, and Overall Survival
Median progression-free survival was 5.5 and 6.0
months for arms A and B, respectively (Figure 1). The
FIGURE 1. A, Progression-free survival and overall survival (B) for all patients.
TABLE 4. Response to Treatment, Performance Status, and
Quality of Life
Arm A
(n  125)
Arm B
(n  124)
Response to treatment
CR 0 1
PR 41 57
MR  SD 60 45
Progression 17 15
Nonevaluable 7 6
ECOG performance status at cycle 5
0 35 40
1 51 55
2 25 18
3 2 6
Nonevaluable 12 5
QOL: patient’s self-assessment at cycle 5
5 9 28
4 45 44
3 35 28
2 21 18
1 2 1
Nonevaluable 13 5
CR, complete remission; PR, partial responses; MR, minimal responses; SD, stable
disease; ECOG, Eastern Cooperative Oncology Group; QOL, quality of life.
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progression-free hazard of arm B patients was 0.848 com-
pared with that of arm A patients (p  0.211).
On progression, most patients were treated with pallia-
tive radiotherapy and supportive care. Any kind of second-
line systemic treatment was offered to 21.6% of patients, with
similar figures for both treatment arms.
No patient was lost to follow-up. Median overall sur-
vival was 10.1 and 10.0 months, and 1-year survival was 46.6
and 41.1% for arms A and B, respectively. The survival
hazard of patients randomized to the arm B was 0.977
compared with that of arm A patients (p  0.861).
Subanalysis According to Histologic Type
Among 71 patients with squamous cell carcinoma,
patients were equally distributed between arms A (32
patients) and B (39 patients) according to prognostic
factors (data not shown). In squamous carcinoma, arm B
seems superior to arm A, as seen by the higher overall
response rate (51.3 versus 35.5%), longer median progres-
sion-free survival (6.2 versus 4.9 months; log rank p 
0.182; Figure 2), improved well-being during cycle 5 as
compared with the status before chemotherapy (64.1 ver-
sus 43.7%), and longer median survival (11.3 versus 8.5
months; log rank p  0.406). However, because of the
small number of patients, these differences did not reach
the level of statistical significance.
DISCUSSION
This is the first randomized clinical trial to compare
gemcitabine in low dose in prolonged infusion with the same
drug given in much higher dose in short infusion. So far, no
such comparison has been made. All reports on phase II trials
of low-dose gemcitabine in prolonged infusion therefore
lacked a proper perspective in relation to the main stream of
clinical research, where brief infusion of gemcitabine in a
higher dose is an established standard.
Our trial included 92% of patients in stage IV and did
not exclude the elderly, those in performance status 2, those
with another malignancy in their medical history or patients
after treatment for brain metastases. Although the two groups
were balanced for most prognostic factors, group B included
more patients with significant weight loss, fewer patients with
squamous histology, all six patients after treatment for an-
other malignancy, and all three patients after surgery and
radiotherapy for brain metastases. Despite this imbalance,
response rates, performance status, and quality of life during
cycle 5 and progression-free survival were slightly (albeit not
significantly) in favor of the low-dose long infusion group;
survival for both groups was identical. Thus, it seems that
treatment with gemcitabine in low dose in long infusion is not
inferior to standard brief infusion of the drug in a much
higher dose.
For both arms, toxicity was low. Although moderate
anemia was common, very few patients in both treatment
arms had significant neutropenia or thrombocytopenia.
Thrombocytosis was common but without significant conse-
quences, possibly because of routine use of low molecular
weight heparin. Alopecia was significantly more common in
the low-dose long infusion group.
FIGURE 2. A, Progression-free survival and overall survival (B) for patients with squamous carcinoma.
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Some oncologists argue that cost of treatment should
not be considered in our medical decisions, but we do not
share that view. Even in developed countries, some pa-
tients have to pay for their treatment; the situation is worse
in developing countries where social solidarity in health
care is virtually nonexistent. Lung cancer is often a disease
of the lower social class,25 and the incidence of lung cancer
in developing countries is rapidly increasing.26 Besides,
even if the treatment is paid by some kind of health
insurance, reducing costs for cancer drugs may spare
resources for other needs such as prevention, improved
early diagnostics, or palliative treatment. For all these
reasons, we believe that low-dose gemcitabine in pro-
longed infusion is a valuable alternative to the standard
chemotherapy of NSCLC. However, it is clear that ex-
penses for the drug are not the only difference when
comparing standard and low-dose gemcitabine. Costs for
infusion systems and for the day hospital, and the burden
of long infusion and of alopecia for incurably ill patients
should also be considered.
During the past decade and, in particular, after pub-
lication of the ECOG 1594 trial,27 many consider that all
chemotherapy regimes for NSCLC are virtually identical;
any effort to find a more effective combination of the
existing drugs may be futile. However, a recent large trial
compared combinations of gemcitabine-cisplatin and pem-
etrexed-cisplatin and showed a significant advantage with
pemetrexed for nonsquamous and with gemcitabine for
squamous histology28. It is now clear that particular types
of lung cancer show different sensitivity not only to
targeted drugs but also to classic cytotoxic agents. Albeit
not reaching statistical significance, experience from our
trial on improved efficacy of gemcitabine in long infusion
for patients with squamous cell carcinoma deserves further
study. We know that these patients rarely benefit from
targeted therapy and are considered resistant to pem-
etrexed. Therefore, our experience is one of the few
potential advancement for patients with the squamous type
of lung cancer. A larger study on patients with lung and
possibly with other cancers of the squamous type may be
considered.
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